TABLE 3.
spa type (no. of isolates) | Predominant antibiotic resistance profile (no. of isolates)a | Distribution by city (no. of cases)b | No. of isolates with the following SCCmec type:
|
MLST allele no. (arc-aro-glp-gmk-pta-tpi-yqi) | MLST-CC | ||||
---|---|---|---|---|---|---|---|---|---|
I | II | III | IV | NT | |||||
t002 (40) | TEDGCi (29) | BJ (1), DL (12), GZ (3), HZ (3), SH (11), SY (7), WH (1), XA (2) | 40 | 1-4-1-4-12-1-10 | ST5-CC5 | ||||
t030 (161) | TEDGRCi (125) | BJ (31), CC (11), DL (3), GZ (17), HZ (11), NJ (6), NN (1), QD (19), SH (6), SY (14), SZ (1), WH (19), XA (22) | 1 | 158 | 2 | 2-3-1-1-4-4-3 | ST239-CC8 | ||
t037 (84) | TEDGHSCi (68) | BJ (3), GZ (11), HZ (6), NJ (5), NN (3), QD (3), SH (29), SZ (9), Ur (6), WH (1), XA (8) | 80 | 4 | 2-3-1-1-4-4-3 | ST239-CC8 | |||
t377 (1) | T (1) | NJ (1) | 1 | 2-3-1-1-4-4-3 | ST239-CC8 | ||||
t437 (4) | TEDCi (2) | GZ (3), Ur (1) | 2 | 2 | 19-23-15-2-19-20-15 | ST59-CC59 | |||
t459 (1) | TEDGRSCi (1) | QD (1) | 1 | 2-3-1-1-4-4-3 | ST239-CC8 | ||||
t570 (2) | TEDGCi (2) | SY (2) | 2 | 1-4-1-4-12-1-10 | ST5-CC5 | ||||
t601 (3) | TEDGCi (3) | HZ (3) | 3 | 1-4-1-4-12-1-10 | ST5-CC5 | ||||
t632 (7) | TEDGRCi (5) | BJ (4), SY (3) | 7 | 2-3-1-1-4-4-3 | ST239-CC8 | ||||
t796 (1) | TEDG (1) | CC (1) | 1 | 5-4-1-4-4-6-3 | ST7-CC7 | ||||
t899 (1) | TEDGRSCi (1) | GZ (1) | 1 | 3-3-1-1-1-1-10 | ST9-CC9 | ||||
t1152 (1) | TEDGRCi (1) | DL (1) | 1 | 2-3-1-1-4-4-3 | ST239-CC8 | ||||
t2649 (1) | E (1) | GZ (1) | 1 | 22-1-14-23-12-4-31 | ST88-CC88 |
T, tetracycline; E, erythromycin; D, clindamycin; G, gentamicin; H, chloramphenicol; R, rifampin, S, trimethoprim-sulfamethoxazole; Ci, ciprofloxacin; V, vancomycin.
BJ, Beijing; CC, Changchun; DL, Dalian; GZ, Guangzhou; HZ, Hangzhou; NJ, Nanjing; NN, Nanning; QD, Qingdao; SH, Shanghai; SY, Shenyang; SZ, Shenzhen; Ur, Urumchi; WH, Wuhan; XA, Xi'an.